RBC Capital Maintains Sector Perform on DCP Midstream, Lowers Price Target to $34

RBC Capital analyst Elvira Scotto maintains DCP Midstream (NYSE:DCP) with a Sector Perform and lowers the price target from $36 to $34.

byBenzinga Newsdesk

November 9, 2021

1 minute read

RBC Capital analyst Elvira Scotto maintains DCP Midstream (NYSE:DCP) with a Sector Perform and lowers the price target from $36 to $34.

Cenntro Electric Group FY21 Sales $8.6M, Up 57.1% YoY; 918 Vehicles Sold, Up 29.8% YoY

By Bill Haddad

Today, 8:14 AM

FREEHOLD, N.J.--(BUSINESS WIRE)-- Cenntro Electric Group Limited (NASDAQ:CENN) (“Cenntro” or “the Company”), a leading EV technology company with advanced, market-validated electric commercial

CENN

Pfizer Shares Quiet Amid FT Report ‘Fourth Pfizer jab ineffective in blocking Omicron, Israeli study shows’

By Benzinga Newsdesk

Today, 8:14 AM

https://www.ft.com/content/58cfd452-a85e-4235-8849-0f4a3c89ffc8

BNTX

Piper Sandler Maintains Overweight on NVIDIA, Raises Price Target to $275

By Benzinga Newsdesk

Today, 8:14 AM

Piper Sandler analyst Harsh Kumar maintains NVIDIA (NASDAQ:NVDA) with a Overweight and raises the price target from $225 to $275.

NVDA

Atai Life Sciences Posts Earnings for Q1 2022, Advancing Key Milestones In Psychedelic Drug Development

By Natan Ponieman

Today, 8:14 AM

Atai Life Sciences (NASDAQ: ATAI), a biotech company leading the development of psychedelic compounds for mental health purposes, issued its financial report for the first quarter of the year, ending March 31, 2022.

ATAI

RBC Capital Maintains Sector Perform on DCP Midstream, Lowers Price Target to $34

Related Posts

Cenntro Electric Group FY21 Sales $8.6M, Up 57.1% YoY; 918 Vehicles Sold, Up 29.8% YoY

Pfizer Shares Quiet Amid FT Report ‘Fourth Pfizer jab ineffective in blocking Omicron, Israeli study shows’

Piper Sandler Maintains Overweight on NVIDIA, Raises Price Target to $275

Atai Life Sciences Posts Earnings for Q1 2022, Advancing Key Milestones In Psychedelic Drug Development